机译:供体来源的CD19靶向T细胞输注消除了异基因造血干细胞移植后对供体淋巴细胞无反应的B细胞急性淋巴细胞白血病的最小残留疾病。
Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Peking University Institute of Hematology,Peking University People's Hospital,Beijing 100044, China;
Collaborative Innovation Center of Hematology, Peking University, Beijing 100084, China;
Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Peking University Institute of Hematology,Peking University People's Hospital,Beijing 100044, China;
Collaborative Innovation Center of Hematology, Peking University, Beijing 100084, China;
Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Peking University Institute of Hematology,Peking University People's Hospital,Beijing 100044, China;
Collaborative Innovation Center of Hematology, Peking University, Beijing 100084, China;
Shenzhen Geno-Immune Medical Institute, Shenzhen 518057, China;
Innovative Cellular Therapeutics Co., Ltd., Shanghai 201499, China;
Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Peking University Institute of Hematology,Peking University People's Hospital,Beijing 100044, China;
Collaborative Innovation Center of Hematology, Peking University, Beijing 100084, China;
Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Peking University Institute of Hematology,Peking University People's Hospital,Beijing 100044, China;
Collaborative Innovation Center of Hematology, Peking University, Beijing 100084, China;
Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Peking University Institute of Hematology,Peking University People's Hospital,Beijing 100044, China;
Collaborative Innovation Center of Hematology, Peking University, Beijing 100084, China;
Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Peking University Institute of Hematology,Peking University People's Hospital,Beijing 100044, China;
Collaborative Innovation Center of Hematology, Peking University, Beijing 100084, China;
Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Peking University Institute of Hematology,Peking University People's Hospital,Beijing 100044, China;
Collaborative Innovation Center of Hematology, Peking University, Beijing 100084, China;
Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Peking University Institute of Hematology,Peking University People's Hospital,Beijing 100044, China;
Collaborative Innovation Center of Hematology, Peking University, Beijing 100084, China;
Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Peking University Institute of Hematology,Peking University People's Hospital,Beijing 100044, China;
Collaborative Innovation Center of Hematology, Peking University, Beijing 100084, China;
Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Peking University Institute of Hematology,Peking University People's Hospital,Beijing 100044, China;
Collaborative Innovation Center of Hematology, Peking University, Beijing 100084, China;
Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Peking University Institute of Hematology,Peking University People's Hospital,Beijing 100044, China;
Collaborative Innovation Center of Hematology, Peking University, Beijing 100084, China;